OTCMKTS:CLABF Core One Labs (CLABF) Stock Price, News & Analysis → Protect Yourself While There’s Still Time … (From Weiss Ratings) (Ad) Free CLABF Stock Alerts $0.14 -0.01 (-6.51%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range$0.14▼$0.1450-Day Range$0.14▼$0.2052-Week Range$0.12▼$0.50Volume3,027 shsAverage Volume4,366 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartFinancialsHeadlinesSEC FilingsShort InterestStock AnalysisChartFinancialsHeadlinesSEC FilingsShort Interest Get Core One Labs alerts: Email Address Ad Weiss RatingsProtect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.4 simple steps to protect your privacy and money before it’s too late. About Core One Labs Stock (OTCMKTS:CLABF)Core One Labs Inc. operates as a psychedelic research and development company. The company focuses on providing psychedelic medicines to novel delivery systems and psychedelic assisted psychotherapy; and intends to further develop and apply the technology to psychedelic compounds, such as psilocybin. It also provides natural health products; news dissemination services; financing services; and operates medical clinics, as well as engages in micro cultivation. The company was formerly known as Lifestyle Delivery Systems Inc. and changed its name to Core One Labs Inc. in September 2019. Core One Labs Inc. was incorporated in 2010 and is headquartered in Vancouver, Canada.Read More CLABF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CLABF Stock News HeadlinesApril 24, 2024 | seekingalpha.comCLB Core Laboratories Inc.April 17, 2024 | americanbankingnews.comCore One Labs (OTCMKTS:CLABF) Shares Down 3.9% April 26, 2024 | Weiss Ratings (Ad)Protect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.February 23, 2024 | finance.yahoo.comCore One Labs Inc. (CLABF)February 1, 2024 | morningstar.comCore One Labs IncDecember 8, 2023 | finance.yahoo.comCore One Labs Inc. Announces Initial Agreement for Potential Sale of Proprietary Biosynthetic Psilocybin, Facilitating Entry into the International MarketDecember 1, 2023 | finance.yahoo.comCore One Labs’ Akome Reveals Impressive Results for its Psychedelic Bio-Compounds Designed to Target Alzheimer’s and Parkinson’s, Showing Potential to Outperform Current Treatment MethodsOctober 9, 2023 | msn.comHalliburton And Core Laboratories Collaborate To Accelerate Digital Rock Data SolutionsApril 26, 2024 | Weiss Ratings (Ad)Protect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.September 1, 2023 | msn.comNew KU core laboratory enhances research for infectious diseaseAugust 18, 2023 | finanznachrichten.deÜbersicht Suchergebnisse zum Thema CORE ONE LABS INCAugust 16, 2023 | msn.comCore Laboratories: 'Spooked The Herd' In June, Things Might Be Looking UpAugust 4, 2023 | finance.yahoo.comCore One's Akome Reveals Groundbreaking Positive Results from its Second Round of Stage 1 Animal Model Studies for Bio-Compounds Targeting Alzheimer’s and Parkinson's DiseaseAugust 1, 2023 | finance.yahoo.comCore One Labs', Awakened Biosciences, Announces Groundbreaking Step Forward in Isolating and Purifying Psilocybin from Mushroom BiomassJuly 28, 2023 | benzinga.comCore One's Akome Receives Positive Preliminary Stage 1 Animal Model Study Results for Bio-Compound Targeting Alzheimer's and Parkinson's DiseaseJuly 28, 2023 | finance.yahoo.comCore One's Akome Receives Positive Preliminary Stage 1 Animal Model Study Results for Bio-Compound Targeting Alzheimer’s and Parkinson’s DiseaseJuly 24, 2023 | benzinga.comCore One Labs Enters Into LOI For First Sale Of Its Psychedelic CompoundsJuly 21, 2023 | finanznachrichten.deCore One Labs Inc.: Core One Labs Enters into Letter of Intent for First Sale of Its Psychedelic CompoundsJuly 21, 2023 | finance.yahoo.comCore One Labs Enters into Letter of Intent for First Sale of Its Psychedelic CompoundsJuly 11, 2023 | finance.yahoo.comCore One's Vocan Biotechnologies Incorporates New Bioreactor Equipment into Production Process Significantly Increasing Throughput of Proprietary Biosynthetic PsilocybinJuly 7, 2023 | finanznachrichten.deCore One Labs Inc.: Core One's Vocan Files International Patent for its Breakthrough Proprietary Biosynthetic Psilocybin Production MethodJuly 7, 2023 | finance.yahoo.comCore One's Vocan Files International Patent for its Breakthrough Proprietary Biosynthetic Psilocybin Production MethodMay 5, 2023 | finanznachrichten.deCore One Labs Inc.: Core One in Talks with Multiple Companies to Supply PsilocybinMay 1, 2023 | finance.yahoo.comCore One Labs' GMP Drug Takes Further Steps Toward Commercialization: Initiating Development of Psychedelic Prodrugs with Long-established Compounding PharmacyApril 24, 2023 | msn.comCore One's Awakened Lays The Groundwork For The Large-Scale Production Of Psychedelic Compounds With Synthetic Production Of PsilocinApril 21, 2023 | finanznachrichten.deCore One Labs Inc.: Core One's Awakened Completes Successful Synthetic Production of Psilocin in its GMP Certified Manufacturing FacilityApril 21, 2023 | finance.yahoo.comCore One's Awakened Completes Successful Synthetic Production of Psilocin in its GMP Certified Manufacturing FacilitySee More Headlines Receive CLABF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Core One Labs and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today4/26/2024Next Earnings (Estimated)5/17/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolOTCMKTS:CLABF CUSIPN/A CIK1640152 Webcore1labs.com Phone(866) 452-6731FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesMr. Joel Shacker (Age 33)CEO & Director Comp: $176.18kMr. Geoffrey Balderson (Age 46)CFO, Secretary & Director Comp: $29.7kDr. Santiago FerroChief Medical Officer & DirectorMr. Brad Paul Eckenweiler (Age 70)Founder & Advisor Mr. Jan Burian Ph.D.Chief Technical OfficerDr. Elizabeth MatthewsHead of Scientific & Regulatory AffairsMore ExecutivesKey Competitors180 Life SciencesNASDAQ:ATNFW3SBioOTCMKTS:TRSBF60 Degrees PharmaceuticalsNASDAQ:SXTPWAbcamOTCMKTS:ABCZFAdociaOTCMKTS:ADOIFView All Competitors CLABF Stock Analysis - Frequently Asked Questions How have CLABF shares performed in 2024? Core One Labs' stock was trading at $0.2389 at the beginning of 2024. Since then, CLABF stock has decreased by 39.9% and is now trading at $0.1435. View the best growth stocks for 2024 here. When is Core One Labs' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, May 17th 2024. View our CLABF earnings forecast. How do I buy shares of Core One Labs? Shares of CLABF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:CLABF) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersThe A.I. story nobody is telling you (Read ASAP)TradeSmithForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingHe Is Giving Away BitcoinCrypto Swap ProfitsFed launches fourth dollar overhaulStansberry ResearchMan Who Predicted 2008: “This Will be Worse.”Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Core One Labs Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
